Revenue grew 7.99% year-over-year to ¥1.05 billion, but the company swung to a net loss due to higher R&D spending and increased costs. Biopharmaceuticals saw strong new product momentum and international deals, while functional foods remained stable.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.